As the company continues to bring new treatments to market, it is likely that Biocryst will continue to be a leader in the field of rare disease treatment, providing both patients and investors alike with a brighter future.

gets a drug approved and immediately rewards shareholders!!!

A great drug like Orladeyo and this is what we get in terms of stock performance. FAILURES

We have a revenue generating drug thats just achieved 105% YoY growth.

If you want a derisked, undervalued company with an approved potential blockbuster drug that can provide steady and incremental ROI year over year, plus the added bonus of pipeline drugs adding more value in future… this stock will be a keeper

BCX 9930 was a very promising and exciting drug and it probably is.

$BCRX 9 slides in the presentation about why its "hard" to design drugs lmfao. hilarious.

"We believe BCX10013 has the potential to be a best-in-class treatment option with an oral, once-daily profile,”

Brags how great drug discovery platform

$BCRX -- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan -- Good news for Orla I guess .

Lots of positive chatter amongst physicians and patients who are holding Tyvaso DPI in high regard and as a life changing medical treatment.

Explanation, Technosphere is a known and safe incipient as defined by the FDA and its use as such in drug delivery is now a known and accepted incipient!

The opportunity is huge to get a lot more Technosphere drugs in the pipeline targeting many diseases & disorders, that could do as good, if not better than Tyvaso DPI.

Tyvaso DPI has clearly demonstrated it to a superior way to deliver drugs in to lung using less dose that delivers high concentration of the medication and it delivers it deeper in the lung.

Either way congrats to the CEO for now finding a great purchase in VGo and now a potential drug in his acquisition of Clofazamine from Qrumpharma.

Allow strong sales for Tyvaso DPI to deliver growing royalties & manufacturing fees, CIPLA PHASE III read-out & positive drug pipeline news to drive increasing market cap/stock price throughout 2023.

"Transforming Evidence Generation for Drug Label Changes: A Case Study" Precursor to Afrezza label change - very promising!! !

$MNKD Sildenafil is a very interesting drug.

Increasing revenues quarter over quarter with profitability here in 2023 combined with a solid partner who depends on us for their blockbuster drug allows me to chill and sleep peacefully at night.

The good part is that Ralinapag is a great additive drug and will not cross compete with Tyvaso DPI.

Two (2) other drugs, each growing revenue steadily.

$META huge reversal off that 52 week low, wow $BIIB has completely outperformed in recent months thanks to the potential of the Alzheimer’s treatment $BA earnings tomorrow.

One drug, Recorlev, just rolling out, best in class drug for advanced Cushings being received exceptionally well by doctors and likely thousands of patients will switch at an annual Rx of $250k-350k, will provide hundreds of millions of new revenue.

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

$AVXL even if this is slightly better then $biib drug which I think it could be much much better the thing is $avxl has much less side affects.

That’s how good this drug potential is.

$BIIB CYTH’s drug much safer and will probably be better all around.

$BIIB so drug approval is good for a stock.. good to know

$AVXL $BIIB at a price tag of 56k annually Aduhelm would have been the most valuable drug in history!!